We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LANCET STUDY: MARBURG VACCINE SHOWS PROMISE IN PRECLINICAL TRIAL

LANCET STUDY: MARBURG VACCINE SHOWS PROMISE IN PRECLINICAL TRIAL

April 28, 2006

A post-exposure vaccine for Marburg virus that gave complete protection to experimental Rhesus macaques could be useful for humans as well, according to a study published in the British journal The Lancet. Marburg virus is a filovirus that causes an often-fatal hemorrhagic disease. There is no vaccine or therapy currently approved for humans, and treatment consists of intensive supportive care. The virus has could be used as a potential bioweapon, noted the study, which was conducted by researchers from Canada's Public Health Agency and the U.S. Army Medical Research Institute of Infectious Diseases.

The vaccine uses attenuated recombinant vesicular stomatitis virus -- an animal pathogen -- combined with glycoproteins from one strain of Marburg virus.

In the study, the researchers gave eight macaques a lethal dose of the virus, injected intramuscularly. Within 20 or 30 minutes, five of the animals were given the vaccine, while the other three were given a similar vaccine engineered to express proteins from the Ebola virus. Three of the five animals treated with the Marburg vaccine developed a fever by day six, but their body temperatures returned to normal by day 10. All five survived.

"These results evidently have important clinical implications and offer a new treatment approach for Marburg virus hemorrhagic fever and perhaps for other viral hemorrhagic fevers," the study concluded.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing